Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 3125 of 3499 entries
View as:

Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia

Phase: N/A Priority: Normal
NCT ID: NCT01111292 Org: User:
Start: 10/31/10 End: 09/30/14 Due: 09/30/15

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05797233 Org: User:
Start: 08/28/23 End: 12/30/29 Due: 12/30/30

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT03228537 Org: User:
Start: 07/16/18 End: 09/19/25 Due: 09/19/26

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02430480 Org: User:
Start: 06/03/15 End: 06/01/25 Due: 06/01/26

Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01198158 Org: User:
Start: 09/15/10 End: 12/16/17 Due: 12/16/18

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02095132 Org: User:
Start: 03/28/14 End: 06/30/23 Due: 06/30/24

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Phase: N/A Priority: Normal
NCT ID: NCT03554473 Org: User:
Start: 09/11/18 End: 03/13/25 Due: 03/13/26

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

Phase: N/A Priority: Normal
NCT ID: NCT03595124 Org: User:
Start: 01/08/19 End: 01/23/26 Due: 01/23/27

A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00001271 Org: User:
Start: 07/31/91 End: 04/30/01 Due: 04/30/02

Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00924170 Org: User:
Start: 10/31/08 End: 05/05/21 Due: 05/05/22

Study of 9cUAB30 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT00896974 Org: User:
Start: 08/31/08 End: 03/31/10 Due: 03/31/11

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Phase: N/A Priority: Normal
NCT ID: NCT04284774 Org: User:
Start: 10/13/20 End: 09/30/27 Due: 09/30/28

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

Phase: N/A Priority: Normal
NCT ID: NCT00004856 Org: User:
Start: 07/31/02 End: - Due: -

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02311933 Org: User:
Start: 05/28/15 End: 02/04/26 Due: 02/04/27

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT02306161 Org: User:
Start: 12/12/14 End: 09/19/25 Due: 09/19/26

Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00002734 Org: User:
Start: 03/31/96 End: - Due: -

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Phase: N/A Priority: Normal
NCT ID: NCT03213652 Org: User:
Start: 04/17/18 End: 06/30/25 Due: 06/30/26

Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00109824 Org: User:
Start: 03/31/06 End: - Due: -

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00093496 Org: User:
Start: 10/31/07 End: 03/31/12 Due: 03/31/13

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01076530 Org: User:
Start: 02/28/10 End: - Due: -

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01664182 Org: User:
Start: 08/01/12 End: 12/07/20 Due: 12/07/21

Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT05044780 Org: User:
Start: 08/30/22 End: 08/01/25 Due: 08/01/26

Penclomedine in Treating Patients With Solid Tumors or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00002946 Org: User:
Start: 10/31/97 End: - Due: -

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02180867 Org: User:
Start: 07/11/14 End: 12/23/25 Due: 12/23/26

Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers

Phase: N/A Priority: Normal
NCT ID: NCT04535414 Org: User:
Start: 06/22/23 End: 01/10/25 Due: 01/10/26